Eli Lilly’s Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon

Quick Read Citigroup's Geoff Meacham targets $1,600 for LLY, representing 37% upside, anchored by Mounjaro and Zepbound's combined $14.9B single-quarter revenue. Novo Nordisk dropped 8% in one session after its post-Wegovy update disappointed, while Viking Therapeutics carries 207% implied upside on clinical-stage binary risk. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut. Eli Lilly (NYSE:LLY) currently trades at $1,164.79, while Wall Street's average analyst price target sits at $1,325.39.